Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 2/20 | 0.59 |
| ▸ | ANO1 | Q5XXA6 | 3/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 8/20 | 0.49 |
| ▸ | CNR2 | P34972 | 3/20 | 0.48 |
| ▸ | FLT3 | P36888 | 3/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5448389 | 0.92 | CFTR (0.59) | CFTRANO1KCNH2CNR2FLT3 | |
| SCHEMBL5459139 | 0.91 | CFTR (0.60) | CFTRANO1KCNH2CNR2FLT3 | |
| SCHEMBL5447455 | 0.89 | CFTR (0.58) | CFTRANO1KCNH2CNR2FLT3 | |
| SCHEMBL5450598 | 0.87 | CFTR (0.54) | CFTRKCNH2CNR2FLT3 | |
| SCHEMBL5457966 | 0.87 | ANO1 (0.66) | CFTRANO1CNR2FLT3CNR1 | |
| SCHEMBL5457889 | 0.86 | CFTR (0.55) | CFTRANO1CNR2FLT3CNR1 | |
| SCHEMBL5449480 | 0.85 | CFTR (0.58) | CFTRANO1KCNH2CNR2FLT3 | |
| SCHEMBL5451228 | 0.84 | CFTR (0.61) | CFTRANO1KCNH2CNR2FLT3 | |
| SCHEMBL5450655 | 0.83 | CFTR (0.54) | CFTRANO1KCNH2CNR2CNR1 | |
| SCHEMBL5467763 | 0.83 | CFTR (0.58) | CFTRANO1KCNH2CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | GPC BIOTECH AG (DE) | 2007-11-29 | — | — | US | claimed |
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | GPC BIOTECH AG (DE) | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | TBCA, PARK7, NFATC1 | CFTR 2030/4885ANO1 3245/4885KCNH2 3409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.